117 related articles for article (PubMed ID: 26112937)
1. Prognostic significance of MDM2 gene expression in childhood neuroblastoma.
Inomistova MV; Svergun NM; Khranovska NM; Skachkova OV; Gorbach OI; Klymnyuk GI
Exp Oncol; 2015 Jun; 37(2):111-5. PubMed ID: 26112937
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 genotype influences survival of metastatic but not of localized neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Scarrà GB; Ghiorzo P; Haupt R; Tonini GP; Fronza G
Pediatr Blood Cancer; 2009 Oct; 53(4):576-83. PubMed ID: 19526525
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of the International Neuroblastoma Pathology Classification in Neuroblastoma (Schwannian stroma-poor) and comparison with other prognostic factors: a study of 182 cases from the Spanish Neuroblastoma Registry.
Burgues O; Navarro S; Noguera R; Pellín A; Ruiz A; Castel V; Llombart-Bosch A
Virchows Arch; 2006 Oct; 449(4):410-20. PubMed ID: 16941154
[TBL] [Abstract][Full Text] [Related]
4. Lack of association between MDM2 promoter SNP309 and clinical outcome in patients with neuroblastoma.
Rihani A; Van Maerken T; De Wilde B; Zeka F; Laureys G; Norga K; Tonini GP; Coco S; Versteeg R; Noguera R; Schulte JH; Eggert A; Stallings RL; Speleman F; Vandesompele J
Pediatr Blood Cancer; 2014 Oct; 61(10):1867-70. PubMed ID: 24391119
[TBL] [Abstract][Full Text] [Related]
5. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of MYCN oncogene expression in childhood neuroblastoma.
Bordow SB; Norris MD; Haber PS; Marshall GM; Haber M
J Clin Oncol; 1998 Oct; 16(10):3286-94. PubMed ID: 9779703
[TBL] [Abstract][Full Text] [Related]
7. Impact of a single nucleotide polymorphism in the MDM2 gene on neuroblastoma development and aggressiveness: results of a pilot study on 239 patients.
Cattelani S; Defferrari R; Marsilio S; Bussolari R; Candini O; Corradini F; Ferrari-Amorotti G; Guerzoni C; Pecorari L; Menin C; Bertorelle R; Altavista P; McDowell HP; Boldrini R; Dominici C; Tonini GP; Raschellà G; Calabretta B
Clin Cancer Res; 2008 Jun; 14(11):3248-53. PubMed ID: 18519749
[TBL] [Abstract][Full Text] [Related]
8. Impact of MDM2 SNP309 genotype on progression and survival of stage 4 neuroblastoma.
Perfumo C; Parodi S; Mazzocco K; Defferrari R; Inga A; Haupt R; Fronza G; Tonini GP
Eur J Cancer; 2008 Nov; 44(17):2634-9. PubMed ID: 18835771
[TBL] [Abstract][Full Text] [Related]
9. GSTP1 hypermethylation is associated with reduced protein expression, aggressive disease and prognosis in neuroblastoma.
Gumy-Pause F; Pardo B; Khoshbeen-Boudal M; Ansari M; Gayet-Ageron A; Sappino AP; Attiyeh EF; Ozsahin H
Genes Chromosomes Cancer; 2012 Feb; 51(2):174-85. PubMed ID: 22045684
[TBL] [Abstract][Full Text] [Related]
10. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression.
Ribatti D; Raffaghello L; Pastorino F; Nico B; Brignole C; Vacca A; Ponzoni M
Int J Cancer; 2002 Dec; 102(4):351-4. PubMed ID: 12402304
[TBL] [Abstract][Full Text] [Related]
11. The presence of Y674/Y675 phosphorylated NTRK1 via TP53 repression of PTPN6 expression as a potential prognostic marker in neuroblastoma.
Youssef G; Gillett C; Rampling D; Chagtai T; Virasami A; Barton J; Edwards D; Sebire N; Anderson J; Montano X
Hum Pathol; 2019 Apr; 86():182-192. PubMed ID: 30594749
[TBL] [Abstract][Full Text] [Related]
12. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309 genotype is associated with ferritin and LDH serum levels in children with stage 4 neuroblastoma.
Parodi S; Perfumo C; Garaventa A; Inga A; Mazzocco K; Defferrari R; Tonini GP; Fronza G; Haupt R
Pediatr Blood Cancer; 2010 Aug; 55(2):267-72. PubMed ID: 20232446
[TBL] [Abstract][Full Text] [Related]
14. Genomic coamplification of CDK4/MDM2/FRS2 is associated with very poor prognosis and atypical clinical features in neuroblastoma patients.
Amoroso L; Ognibene M; Morini M; Conte M; Di Cataldo A; Tondo A; D'Angelo P; Castellano A; Garaventa A; Lasorsa VA; Podestà M; Capasso M; Pezzolo A
Genes Chromosomes Cancer; 2020 May; 59(5):277-285. PubMed ID: 31756773
[TBL] [Abstract][Full Text] [Related]
15. Influence of segmental chromosome abnormalities on survival in children over the age of 12 months with unresectable localised peripheral neuroblastic tumours without MYCN amplification.
Defferrari R; Mazzocco K; Ambros IM; Ambros PF; Bedwell C; Beiske K; Bénard J; Berbegall AP; Bown N; Combaret V; Couturier J; Erminio G; Gambini C; Garaventa A; Gross N; Haupt R; Kohler J; Jeison M; Lunec J; Marques B; Martinsson T; Noguera R; Parodi S; Schleiermacher G; Tweddle DA; Valent A; Van Roy N; Vicha A; Villamon E; Tonini GP
Br J Cancer; 2015 Jan; 112(2):290-5. PubMed ID: 25356804
[TBL] [Abstract][Full Text] [Related]
16. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group.
Schneiderman J; London WB; Brodeur GM; Castleberry RP; Look AT; Cohn SL
J Clin Oncol; 2008 Feb; 26(6):913-8. PubMed ID: 18281664
[TBL] [Abstract][Full Text] [Related]
17. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
18. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
19. VEGF-C, VEGF-D and VEGFR-3 expression in peripheral neuroblastic tumours.
Ramani P; Nash R; Radevsky L; Patel A; Luckett M; Rogers C
Histopathology; 2012 Dec; 61(6):1006-16. PubMed ID: 22804730
[TBL] [Abstract][Full Text] [Related]
20. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study.
George RE; London WB; Cohn SL; Maris JM; Kretschmar C; Diller L; Brodeur GM; Castleberry RP; Look AT
J Clin Oncol; 2005 Sep; 23(27):6466-73. PubMed ID: 16116152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]